Ro7122290 drug page Clinical trials

Trials with Ro7122290

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

1Trials
0Recruiting
5Countries
54Planned patients

Showing 1–1 of 1

Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
Finished Phase 1 54 patients NCT04826003

This is an open-label, multicenter, Phase Ib study to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) in the weekly (QW) and/or every 3 weeks (Q3W) regimens, safety, tolerability, PK, immunogenicity, P…

Denmark, Netherlands, South Korea, Spain and 1 more Jul 2021 – Nov 2024 Interventional
Combined with: CibisatamabObinutuzumab